Acquired decrease of the C3b/C4b receptor (CR1, CD35) and increased C4d deposits on Erythrocytes from ICU COVID-19 Patients

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Partial Funding by the Not-for-profit Organisation "Association pour le Developement de l'Immunologie et de la Microbiologie Remoise" ADMIR Grant 2020/0001.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Rheims University Hospital has obtained the authorization to create plasma and serum libraries from the Human Protection Committee (CPP Est III, national number: 2020-A01093-36) in order to study the soluble Vascular Endothelial Growth Factor (sFlt-1) receptor in intensive care patients with severe COVID-19 pneumonitis. The patients or their families signed an informed consent form to participate, specifying that other elements, such as the red blood cells, that were to be discarded, could be used for research for other purposes, in the context of the COVID-19 epidemic. Blood donors were healthy volunteers who signed the general informed consent from the national Etablissement Francais du Sang (EFS). Aged patients were from a cohort with individual informed consents approved by the regional ethics committee (CPP Est II), under the protocol number 2011-A00594-37. Consents of the healthy volunteers of the C4d/E reference cohort were also approved by the local ethics committee in 2006.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes